Late-stage biotechnology company focused on the design and development of synthetic biology-based biopharmaceuticals. The company is focused on metabolic and immunological adaptations to develop potential medicines for both rare and common diseases. The company is developing drug candidates for rare diseases including phenylketonuria, homocystinuria and inflammatory bowel disease. The company is based in Delaware.